Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More
U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07720024) titled 'Comparison of Medial Knee Pain Between Patients With and Without Preoperative Tibia Vara Un... Read More
Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More
Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'An open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and ... Read More
Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of ascim... Read More
Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with... Read More
Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy ... Read More
U.S., July 23 -- ClinicalTrials.gov registry received information related to the study (NCT07720817) titled 'Ultrasound Guided Retrolaminar Block Versus Transverse Abdominis Plane Block in Laparoscopi... Read More
Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel a... Read More
Singapore, July 23 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Ad... Read More